Niddk: procurement of intravenous stable isotope glucose (6,6 deuterated glucose) for metabolic research. Nonseverable.
Ended Awarded Last action
- Contract number
- 75N94026F00001
- Awardee
-
Pine Pharmaceuticals LLC UEI TCJXKNYD6WL5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $91,898
Award facts
- Contract value 100% obligated
- $91,897.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Tonawanda, NY 14150, USA
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $91,897.70 firm fixed-price delivery order to Pine Pharmaceuticals LLC for the procurement of intravenous stable isotope glucose (6,6 deuterated glucose) to support metabolic research. The contract, awarded on December 18, 2025, with an ultimate completion date of May 31, 2026, was issued without a set-aside designation. Pine Pharmaceuticals, an FDA-registered 503B outsourcing facility located in Tonawanda, New York, specializes in pharmaceutical compounding and the production of specialized pharmaceutical products for scientific and medical research institutions. This delivery order is issued under Pine Pharmaceuticals' existing $7.27 million single-award indefinite delivery contract with NIDDK for metabolic isotopes, which runs through September 29, 2029 and was awarded as a total small business set-aside to support research studies across various HHS agencies.
The procurement of 6,6 deuterated glucose represents a critical input for NIDDK-supported metabolic research, enabling investigators to trace glucose metabolism and utilization in human subjects through stable isotope methodology. Pine Pharmaceuticals has demonstrated extensive experience providing specialized pharmaceutical compounds and isotopes to federal agencies, particularly within the Department of Health and Human Services, with over 37 years of operational history. This delivery order continues the company's established role as a key supplier of metabolic isotopes essential to advancing diabetes, digestive, and kidney disease research initiatives.
Quick answers
Who was awarded contract 75N94026F00001?
75N94026F00001 was awarded to Pine Pharmaceuticals LLC by National Institute of Child Health and Human Development (National Institutes of Health) on December 18, 2025.
How much is contract 75N94026F00001 worth?
The government has obligated $91,898 on 75N94026F00001.
Which agency awarded contract 75N94026F00001?
National Institute of Child Health and Human Development (National Institutes of Health) awarded 75N94026F00001, with funding from National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health).
Is contract 75N94026F00001 an order under another contract?
Yes. 75N94026F00001 is a delivery order under 75N94024D00003, an indefinite delivery contract.
Was contract 75N94026F00001 competed?
The extent of competition for 75N94026F00001 was competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award